Invest in PhorMed

Pipeline

Problem/Solution & Market

Acute Myeloid Leukemia (AML), cancer of the white blood cells; destroys the immune system

Problem:

• This cancer is very fast-acting
• High level of deaths
• No targeted medicines currently available

Problems with current treatments: 

• Current treatments have severe side effects, long lasting and at times life threatening in itself
• Kills healthy cells
• Can cause heart and kidney damage 
• Can cause nerve damage and brain function issues, and more
• At times the side effects are so severe the patient needs to halt treatment and the cancer becomes stronger and even harder to fight

Solution:

• Our goal is to become a safe first-line targeted treatment, giving cancer patients better options than those currently used
• Our goal is to turn long-term-side-effects into something that only happened in the past

Hodgkin’s Lymphoma, cancer that starts in the lymphatic system and impacts the immune system.

Problem:

• Surgery is not an option
• High occurrence of relapse (cancer coming back)
• No targeted medicines available

The problems with current treatments:

• Kills healthy cells
• Side effects that don’t improve
• loss of fertility
• Side effects that show up months or years after treatment
• Current treatments increase the already high occurrence of relapse

Solution:

• Our goal: Make our targeted treatment available as the first option, avoiding current treatments
• Same as for AML, our goal here is to turn long-term-side-effects into something that only happened in the past

Acute Respiratory Distress Syndrome (ARDS), an inflammatory lung condition brought on by Pneumonia, COVID-19 and other reasons.

Problem:

• High occurrence of death 
• No available medicine

Solution: Our drug would be 'first-in-class,' meaning we will be curing ARDS in a new way. Our goal is to become the first targeted treatment and a patient’s main option.

Parkinson's disease is a life-threatening neurological brain disorder.

Problem:

• Long lasting
• Life threatening disease
• No available medicine

Solution: Our drug would be a 'first-in-class’ drug for treating Parkinson’s disease. We would offer a safe, targeted treatment that allows patients to overcome long term suffering and life-threatening results.

Broad Clinical Success

• Success in AML - 83% remission
• Reduced tumor in Hodgkin's Lymphoma
• Reduced inflammation - in lungs and brain
• White Blood Cells & Neutrophil increased - cancer fighting (See image below)

FAQ : About Our Drug

Cancer, lung disease, and brain disorders seem so different. How can one drug treat many different issues?

• These diseases have something in common: they are all inflammatory disorders
• Cells become damaged or mutated, not functioning as they should, causing the onset of diseases
• We have found our drug targets these cells
• Repairs damaged and mutated cells
• Fixing the root of the problem, allowing the body to function as it should

Comparisons

These companies were chosen because of their similar pipeline profiles to PhorMed.

Qualifications:

• Phase 3: 0 clinical trials (all companies have zero trials in phase 3)
• Phase 2: 2 or 3 clinical trials (PhorMed has the advantage with 3 clinical trials at this stage compared to others with only 2)
• Phase 1 & pre-clinical: All have additional clinical trials and studies in development

With projected market values somewhere between $290M-1.2B, this gives PhorMed remarkable growth potential at $53 Million. Invest now and grow with the company.

Use of Proceeds

Our Roadmap

Major Partnerships

• WuXi Biologics: Manufacturing partner, one the the largest and respected contract research organizations (CRO) and contract manufacturing organizations (CMO) in the world
• Pharmaron: Laboratory & pre-clinical partner, a global research and development facility with extensive servicing capabilities in the U.S. and worldwide
• Emory University School of Medicine: Clinical site partner, one of the top neuroscience centers in the country (see image below for more details)
• Winship Cancer Center: Clinical site partner, a leading oncology research facility (see image below for more details)

RECAP: Benefits

Anti-inflammation

Newest discovered: RP-323 is a breakthrough treatment for inflammation

Kills cancer cells, repairs damaged & mutated cells

Our drug repairs and restores damaged and mutated cells, can kill a cancer cell, and boosts cancer fighting immune response. Supported by clinical evidence.

Fast-Track designation

We are on the Fast Track. Literally. The FDA has granted us their “Fast Track” status, which speeds up approval process and greatly reduces overall cost.

Investment opportunity

As an investor you will have the opportunity to buy low compared to other similar companies and grow with the company.